Immunovant, Inc. 4

Chief Legal Officer Christopher Van Tuyl sold 1,206 shares of Immunovant, Inc. common stock on July 8, 2026 in non-discretionary, tax-related sell-to-cover transactions tied to RSU vesting.

On July 8, 2026, Immunovant, Inc. Chief Legal Officer Christopher Van Tuyl sold a total of 1,206 shares of Immunovant common stock in two small open-market transactions at weighted average prices of $39.53 and $39.99 per share, respectively. These sales were explicitly disclosed as non-discretionary, being executed solely to cover tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted RSUs from an April 1, 2025 award of 50,787 RSUs. Following these tax-related “sell to cover” transactions, Van Tuyl continued to hold 179,391 shares of Immunovant common stock directly, indicating that his overall ownership position remained substantial and that the transactions were routine compensation-driven rather than indicative of a directional view on the stock.

Filing Facts

CIK

1764013

Ticker

IMVT

Form

4

Source Type

fda

Accession

0001764013-26-000082

Alert Tier

5